Φορτώνει......
1ISG-008 Economic impact of the use of biosimilar infliximab in a second-level hospital
BACKGROUND: The high price of biological drugs has become progressively unsustainable to the national health system. The development of biosimilar drugs might represent an option in reducing healthcare costs. PURPOSE: To analyse the economic impact of incorporating biosimilar infliximab (BI) in a se...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Eur J Hosp Pharm |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMJ Group
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535246/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|